Scarica l'app Stockscreener
79.03
1.97%
1.53
Dopo l'orario di chiusura:
79.03
Precedente Chiudi:
$77.50
Aprire:
$78.18
Volume 24 ore:
416.91K
Relative Volume:
0.42
Capitalizzazione di mercato:
$6.45B
Reddito:
$39.21M
Utile/perdita netta:
$-311.35M
Rapporto P/E:
-21.48
EPS:
-3.6793
Flusso di cassa netto:
$-234.34M
1 W Prestazione:
-5.34%
1M Prestazione:
-4.02%
6M Prestazione:
+68.18%
1 anno Prestazione:
+136.26%
Intervallo 1D:
$77.10
$81.25
Intervallo di 1 settimana:
$76.85
$86.92
Portata 52W:
$19.45
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Nome
Kymera Therapeutics Inc
Settore
Industria
Telefono
857-285-5314
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
79.03 | 6.45B | 39.21M | -311.35M | -234.34M | -3.6793 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-06 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Ripresa | Guggenheim | Buy |
| 2025-10-24 | Reiterato | B. Riley Securities | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-30 | Ripresa | B. Riley Securities | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-20 | Ripresa | Stifel | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-12-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-26 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Iniziato | Oppenheimer | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Iniziato | Truist | Buy |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Iniziato | Raymond James | Mkt Perform |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-08-03 | Iniziato | Goldman | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | JP Morgan | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2021-09-30 | Iniziato | B. Riley Securities | Neutral |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-15 | Iniziato | BofA Securities | Neutral |
| 2020-09-15 | Iniziato | Cowen | Outperform |
| 2020-09-15 | Iniziato | Guggenheim | Buy |
| 2020-09-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Kymera Therapeutics, Inc. $KYMR Stock Position Lessened by Avoro Capital Advisors LLC - MarketBeat
Can Kymera Therapeutics’ (KYMR) Oral Degraders Redefine Its Long-Term Edge Over Biologic Rivals? - simplywall.st
Kymera at Barclays Conference: Strategic Focus on Immunology By Investing.com - Investing.com Canada
Kymera Therapeutics CFO presents new immunology strategy at Barclays Healthcare Conference - Traders Union
Kymera Therapeutics, Inc. $KYMR Holdings Trimmed by Atika Capital Management LLC - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 earnings call transcript - MSN
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 25,758 Shares - MarketBeat
Kymera (NASDAQ: KYMR) COO exercises 20,000 options and sells 25,758 shares - Stock Titan
Hedge Fund Moves: Can Kymera Therapeutics Inc weather a recessionVolume Spike & Daily Chart Pattern Signals - baoquankhu1.vn
Kymera to present atopic dermatitis trial data at AAD meeting By Investing.com - Investing.com Canada
Kymera at Leerink Global Healthcare: Strategic Insights on Drug Development By Investing.com - Investing.com Canada
KYMR: KT-621 shows strong early efficacy and safety; pivotal Phase 2b readouts expected in 2027 - TradingView
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology Annual Meeting - Investing News Network
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting - Bitget
Experimental atopic dermatitis pill KT-621 heads to late-breaking AAD stage - Stock Titan
A Look At Kymera Therapeutics (KYMR) Valuation After Equity Raise, Wider Losses And Leadership Change - Sahm
Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss - Yahoo Finance
Market Moves: What is the long term forecast for Kymera Therapeutics Inc. stockWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
How (KYMR) Movements Inform Risk Allocation Models - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Profit Recap: How sensitive is Kymera Therapeutics Inc to inflationWeekly Volume Report & Reliable Entry Point Trade Alerts - baoquankhu1.vn
JPMorgan Chase & Co. Has $10.91 Million Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Q1 EPS Estimate for Kymera Therapeutics Boosted by Analyst - MarketBeat
Kymera (KYMR) Q4 2025 Earnings Call Transcript - AOL.com
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 3,919 Shares - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CFO Sells 4,895 Shares of Stock - MarketBeat
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet - AOL.com
Bruce Jacobs Sells 7,576 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Jared Gollob Sells 5,613 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 81,866 Shares of Stock - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Acquired by Rafferty Asset Management LLC - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells 2,039 Shares of Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $128.00 - MarketBeat
UBS Raises Price Target for Kymera Therapeutics (KYMR) to $128 | - GuruFocus
Kymera at TD Cowen Conference: Strategic Insights on Drug Programs - Investing.com
Commit To Purchase Kymera Therapeutics At $60, Earn 15.1% Annualized Using Options - Nasdaq
How Kymera’s Bigger Losses and New Equity Plans May Impact Kymera Therapeutics (KYMR) Investors - simplywall.st
Kymera Therapeutics (KYMR) Stock Analysis: Exploring a 30% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase (NASDAQ:KYMR) - Seeking Alpha
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273 - Pharmaceutical Technology
[144] Kymera Therapeutics, Inc. SEC Filing - Stock Titan
Citigroup Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $120.00 - MarketBeat
Kymera Therapeutics (KYMR): Citigroup Raises Price Target, Reaff - GuruFocus
Stephens raises Kymera Therapeutics price target to $100 on pipeline By Investing.com - Investing.com Canada
Kymera Therapeutics (KYMR): Analyst Raises Price Target to $100 - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $100.00 at Stephens - MarketBeat
TD Asset Management Inc Reduces Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans - Yahoo Finance
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 - MarketBeat
Kymera Therapeutics Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):